You are here
- Home
- Therapy Areas
- Oncology/Infection
Phase II, Open Label, Non-Randomized Study of AZD2281 in the Treatment of Patients with Known BRCA or Recurrent High Grade Serous/ Undifferentiated Tubo-Ovarian Carcinoma and in Known BRCA or Triple Negative Breast Cancer to Determine Response Rate and Correlative Markers of Response
- Disease
- breast cancer, ovarian cancer
- Drug Name
- Olaparib
- Generic Name
- Olaparib (AZD2281)
- Sponsor
- AstraZeneca
- Drug Status
- In Development
- Phase
- II
- Start Date
- May 13, 2008
- Study Name
- D0810C00020
- Study Id
- D0810C00020
- ClinicalTrials.gov ID
- NCT00679783
- Recruiting Status
- Open
- Protocol Status
- Not Available
- Report Status
- Not Available
